Effectiveness of vortioxetine for major depressive disorder in real-world clinical practice
US cohort results from the global Relieve study
Bibliographic Data
| ID | 15522212 |
|---|---|
| Authors | Gregory W Mattingly (0000-0002-0234-6860, Charles River Associates), Gregory Mattingly, Elizabeth Brunner (0000-0002-0768-4359), Lambros Chrones (0000-0001-7822-9364, Takeda (United States)), Debra Lawrence (Takeda (United States)), Debra F Lawrence, Kenneth Simonsen (Lundbeck (Denmark)), Hongye Ren (0000-0003-0080-4765, Lundbeck (Denmark)) |
| Year | 2023 |
| Volume | 13 |
| Pages | 977560-977560 |
| Publication date | 2023-01-04 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Psychiatry (JOURNAL) |
| Journal identifiers | ISSN: 1664-0640 • E-ISSN: 1664-0640 |
| Publisher | Frontiers Media (PUBLISHER • CH) |
| DOI | 10.3389/fpsyt.2022.977560 |
| PMID | 36683990 |
| OpenAlex | W4313585477 |
| Language | EN |
| References cited | 30 |
This real-world study demonstrated improvements in functioning, depressive symptoms, and cognitive function in patients with MDD treated with vortioxetine in routine clinical practice in the cohort of patients enrolled in the United States. Outcomes were consistent with the efficacy and safety profile of vortioxetine in randomized controlled trials
Adverse effect · Cognition · Cohort · Cohort study · Depression (economics · Major depressive disorder · Nausea · Psychiatry · Quality of life (healthcare · Sexual dysfunction · Sexual function · Vortioxetine · Cardiac Health and Mental Health · Electroconvulsive Therapy Studies · Medicine · Psychology · Treatment of Major Depression · Internal Medicine
| Highly cited | No |
|---|